New Zealand markets open in 4 hours

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
12.880+0.240 (+1.90%)
At close: 04:08PM HKT

Shanghai Junshi Biosciences Co., Ltd.

Building 7
15th Floor No.6, Lane 100, Pingjiaqiao Road Pudong New Area
Shanghai 200126
86 21 6105 8800

Full-time employees2,568

Key executives

NameTitlePayExercisedYear born
Mr. Jun XiongExecutive Chairman7.79MN/A1974
Mr. Cong LiCo-CEO & Executive Director4.62MN/A1964
Dr. Jianjun Zou M.D., Ph.D.GM, CEO & Executive Director6.41MN/A1971
Dr. Ning LiExecutive Vice-Chairman of the Board7.98MN/A1961
Mr. Baohong XuFinancial DirectorN/AN/A1979
Mr. Zhuobing ZhangDeputy GM & Executive Director7.37MN/A1967
Dr. Sheng Yao Ph.D.Senior VP & Executive Director5.07MN/A1975
Dr. Gang WangDeputy GM, Chief Quality Officer, Senior VP of Industry Affairs & Executive Director1.24MN/A1957
Dr. Xin LiExecutive DirectorN/AN/A1979
Ms. Lu YuanAssistant to GM & Chief of Internal Audit DepartmentN/AN/A1982
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Corporate governance

Shanghai Junshi Biosciences Co., Ltd.’s ISS governance QualityScore as of 1 July 2024 is 5. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.